Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.

Masatoshi KudoRobert MontalRichard S FinnFlorian CastetKazuomi UeshimaNaoshi Nishida Philipp K HaberYouyou HuYasutaka ChibaMyron E Schwartz Tim MeyerRiccardo LencioniJosep M Llovet

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

OR-mRECIST is an independent predictor of OS in patients with advanced HCC. Although correlation of OR-mRECIST and OS is better than with OR-RECIST, the level of surrogacy is modest. Thus, it can be used as endpoint in proof-of-concept phase II trials, but the data do not support its use as a primary endpoint of phase III investigations assessing systemic therapies.

Keyphrases

phase ii
phase iii
open label
clinical trial
placebo controlled
double blind
electronic health record
study protocol
big data
machine learning
newly diagnosed